CD8A and neoplasm: Additionally, other than the therapeutic agents, some bacteria capable of surviving in antigen-presenting cells (APCs) or utilizing type III secretion system (T3SS) can be engineered as vaccine vectors that deliver tumor antigens to APCs and induce durable tumor-specific CD8+ T cell responses (58, 59).